← Back to Screener
Centessa Pharmaceuticals plc American Depositary Shares (CNTA)
Price$39.53
Favorite Metrics
Price vs S&P 500 (26W)73.64%
Price vs S&P 500 (4W)32.14%
Market Capitalization$5.91B
All Metrics
Book Value / Share (Quarterly)$2.24
P/TBV (Annual)1.96x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.35
Price vs S&P 500 (YTD)55.73%
EPS (TTM)$-1.45
10-Day Avg Trading Volume3.93M
EPS Excl Extra (TTM)$-1.45
EPS (Annual)$-1.46
ROI (Annual)-31.01%
Cash / Share (Quarterly)$1.83
ROA (Last FY)-28.73%
EBITD / Share (TTM)$-1.50
ROE (5Y Avg)-60.40%
Cash Flow / Share (Annual)$-1.07
P/B Ratio11.21x
P/B Ratio (Quarterly)6.31x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-29.86x
ROA (TTM)-36.65%
EPS Incl Extra (Annual)$-1.46
Current Ratio (Annual)8.57x
Quick Ratio (Quarterly)8.31x
3-Month Avg Trading Volume2.16M
52-Week Price Return231.74%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.66
P/S Ratio (Annual)393.86x
Asset Turnover (Annual)0.02x
52-Week High$40.26
EPS Excl Extra (Annual)$-1.46
26-Week Price Return77.62%
Quick Ratio (Annual)8.31x
13-Week Price Return79.88%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)8.57x
Enterprise Value$5,956.736
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1304.75%
Cash / Share (Annual)$3.64
3-Month Return Std Dev95.53%
Net Income / Employee (TTM)$-2
ROE (Last FY)-37.49%
Net Interest Coverage (Annual)-32.36x
EPS Basic Excl Extra (Annual)$-1.46
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$-1.45
ROI (TTM)-39.54%
Revenue / Share (Annual)$0.11
Tangible BV / Share (Annual)$3.54
Price vs S&P 500 (52W)201.91%
Year-to-Date Return58.38%
5-Day Price Return-0.38%
EPS Normalized (Annual)$-1.46
ROA (5Y Avg)-44.15%
Net Profit Margin (Annual)-1316.88%
Month-to-Date Return-0.28%
Cash Flow / Share (TTM)$-1.64
EBITD / Share (Annual)$-1.50
Operating Margin (Annual)-1384.61%
LT Debt / Equity (Annual)0.21x
ROI (5Y Avg)-49.21%
LT Debt / Equity (Quarterly)0.21x
EPS Basic Excl Extra (TTM)$-1.45
P/TBV (Quarterly)2.54x
P/B Ratio (Annual)6.31x
Book Value / Share (Annual)$3.03
Price vs S&P 500 (13W)79.19%
Beta1.17x
Revenue / Share (TTM)$0.11
ROE (TTM)-50.66%
52-Week Low$10.95
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CNTACentessa Pharmaceuticals plc American Depositary Shares | — | — | — | — | $39.53 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company with a portfolio of therapeutic candidates across multiple disease areas. Key programs include SerpinPC for hemophilia, LB101 for solid tumors, ORX750 for narcolepsy and sleep disorders, and MGX292 for pulmonary arterial hypertension, plus an undisclosed solid tumor program.